Literature DB >> 16524697

Novel, isotype-specific sensors for protein kinase A subunit interaction based on bioluminescence resonance energy transfer (BRET).

Anke Prinz1, Mandy Diskar, Andrea Erlbruch, Friedrich W Herberg.   

Abstract

Homogeneous protein-protein interaction assays without the need of a separation step are an essential tool to unravel signal transduction events in live cells. We have established an isoform specific protein kinase A (PKA) subunit interaction assay based on bioluminescence resonance energy transfer (BRET). Tagging human Ralpha(I)-, Ralpha(II)-, as well as Calpha-subunits of PKA with Renilla luciferase (Rluc) as the bioluminescent donor or with green fluorescent protein (GFP2) as the energy acceptor, respectively, allows to directly probe PKA subunit interaction in living cells as well as in total cell extracts in order to study side by side PKA type I versus type II holoenzyme dynamics. Several novel, genetically encoded cAMP sensors and-for the first time PKA type I sensors-were generated. When C- and R-subunits are assembled to the respective holoenzyme complexes inside the cell, BRET occurs with a signal up to three times above the background. An increase of endogenous cAMP levels as well as treatment with the cAMP analog 8-Br-cAMP is reflected by a dose-dependent BRET signal reduction in cells expressing wild type proteins. In contrast to type II, the dissociation of the PKA type I holoenzyme complex was never complete in cells with maximally elevated cAMP levels. Both sensors dissociated completely upon treatment with 8-Br-cAMP after cell lysis, consistent with in vitro activation assays using holoenzymes assembled from purified PKA subunits. Interestingly, incubation of cells with the PKA antagonist Rp-8-Br-cAMPS leads to a significant BRET signal increase in cells expressing PKA type I or type II isoforms, indicating a stabilization of the holoenzyme complexes in vivo. Mutant RI subunits with reduced (hRIalpha-R210K) or abolished (hRIalpha-G200E/G324E) cAMP binding capability were studied to quantify maximal signal to noise ratios for the RI-BRET sensor. Utilizing BRET we demonstrate that PKA type II holoenzyme was rendered insensitive to beta-adrenergic receptor stimulation with isoproterenol when anchoring to the plasma membrane of COS-7 cells was disrupted by either using Ht31 peptide or by depletion of membrane cholesterol.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16524697     DOI: 10.1016/j.cellsig.2006.01.013

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  31 in total

Review 1.  Probing heterotrimeric G protein activation: applications to biased ligands.

Authors:  Colette Denis; Aude Saulière; Segolene Galandrin; Jean-Michel Sénard; Céline Galés
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A.

Authors:  S Adrian Saldanha; Gregory Kaler; Howard B Cottam; Ruben Abagyan; Susan S Taylor
Journal:  Anal Chem       Date:  2006-12-15       Impact factor: 6.986

3.  Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo.

Authors:  E Stefan; S Aquin; N Berger; C R Landry; B Nyfeler; M Bouvier; S W Michnick
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

4.  High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides.

Authors:  Christian Hundsrucker; Gerd Krause; Michael Beyermann; Anke Prinz; Bastian Zimmermann; Oliver Diekmann; Dorothea Lorenz; Eduard Stefan; Pavel Nedvetsky; Margitta Dathe; Frank Christian; Theresa McSorley; Eberhard Krause; George McConnachie; Friedrich W Herberg; John D Scott; Walter Rosenthal; Enno Klussmann
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

5.  Regulatory subunit I-controlled protein kinase A activity is required for apical bile canalicular lumen development in hepatocytes.

Authors:  Kacper A Wojtal; Mandy Diskar; Friedrich W Herberg; Dick Hoekstra; Sven C D van Ijzendoorn
Journal:  J Biol Chem       Date:  2009-05-22       Impact factor: 5.157

6.  Phosphorylation of the cAMP-dependent protein kinase (PKA) regulatory subunit modulates PKA-AKAP interaction, substrate phosphorylation, and calcium signaling in cardiac cells.

Authors:  Sabrina Manni; Joseph H Mauban; Christopher W Ward; Meredith Bond
Journal:  J Biol Chem       Date:  2008-06-12       Impact factor: 5.157

7.  Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors.

Authors:  Elise Meoli; Ioannis Bossis; Laure Cazabat; Manos Mavrakis; Anelia Horvath; Sotiris Stergiopoulos; Miriam L Shiferaw; Glawdys Fumey; Karine Perlemoine; Michael Muchow; Audrey Robinson-White; Frank Weinberg; Maria Nesterova; Yianna Patronas; Lionel Groussin; Jérôme Bertherat; Constantine A Stratakis
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Rp-cAMPS Prodrugs Reveal the cAMP Dependence of First-Phase Glucose-Stimulated Insulin Secretion.

Authors:  Frank Schwede; Oleg G Chepurny; Melanie Kaufholz; Daniela Bertinetti; Colin A Leech; Over Cabrera; Yingmin Zhu; Fang Mei; Xiaodong Cheng; Jocelyn E Manning Fox; Patrick E MacDonald; Hans-G Genieser; Friedrich W Herberg; George G Holz
Journal:  Mol Endocrinol       Date:  2015-06-10

9.  Structural and functional analysis of phosphorylation-specific binders of the kinase ERK from designed ankyrin repeat protein libraries.

Authors:  Lutz Kummer; Petra Parizek; Peter Rube; Bastian Millgramm; Anke Prinz; Peer R E Mittl; Melanie Kaufholz; Bastian Zimmermann; Friedrich W Herberg; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-27       Impact factor: 11.205

Review 10.  Biosensing and imaging based on bioluminescence resonance energy transfer.

Authors:  Zuyong Xia; Jianghong Rao
Journal:  Curr Opin Biotechnol       Date:  2009-02-11       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.